Alnylam Pharmaceuticals partners with Inceptive Nucleics on AI-driven RNAi therapy development
Alnylam Pharmaceuticals (ALNY) has entered a collaboration worth up to $2 billion with Inceptive Nucleics, leveraging generative AI models for the advancement of RNA interference therapeutics. The deal includes an upfront payment of $30 million in cash and equity.
Tickers: $ALNY
Topics: AI in Drug Development Pharmaceuticals RNAi Therapeutics